Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives
- PMID: 28988742
- DOI: 10.1016/j.retram.2017.08.003
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives
Abstract
Progress in our understanding of basic immunology along with the advent of bioengineering technologies have made possible the production of human T-cells expressing Chimeric Antigen Receptors (CAR T-cells). These CAR T-cells are designed to target specific antigens presented by cancer cells. Once CARs are bound to these antigens, CAR T-cells get activated and can initiate potent anti-tumor effects. We will here overview the bioengineering advances which made possible the clinical application of CAR T-cell therapy. We will review the data to date regarding anti-CD19 CAR T-cell therapy for acute lymphoblastic leukemia, non-Hodgkin lymphomas, and chronic lymphocytic leukemia. Besides CD19, CAR T-cells directed against the B-cell maturation antigen have also shown encouraging results to treat patients with refractory multiple myeloma. The more limited body of clinical research in the field of solid tumors will also be reviewed. Moreover, we will elaborate on the main toxicities of limitations of CAR T-cell therapy, namely cytokine release syndrome and neurotoxicity. While enjoying an undeniable hype, CAR T-cell therapy bears significant limitations. We will conclude by exposing the possible approaches to make CAR T-cells safer and more efficient beyond the CD19 target.
Keywords: Adoptive T-cell therapy; Chimeric antigen receptor therapy; Hematological malignancies; Review; Solid tumors.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.
Similar articles
-
CARs in the Lead Against Multiple Myeloma.Curr Hematol Malig Rep. 2017 Apr;12(2):119-125. doi: 10.1007/s11899-017-0373-2. Curr Hematol Malig Rep. 2017. PMID: 28233151 Free PMC article. Review.
-
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.Mol Cancer. 2018 Jan 12;17(1):7. doi: 10.1186/s12943-018-0759-3. Mol Cancer. 2018. PMID: 29329591 Free PMC article. Review.
-
CAR T-cell therapy: Full speed ahead.Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. doi: 10.1002/hon.2591. Hematol Oncol. 2019. PMID: 31187533 Review.
-
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018. Front Immunol. 2018. PMID: 30108584 Free PMC article. Review.
-
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Hepatobiliary Pancreat Dis Int. 2018. PMID: 29861325 Review.
Cited by
-
Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.Recent Pat Anticancer Drug Discov. 2024;19(5):557-572. doi: 10.2174/0115748928277331231218115402. Recent Pat Anticancer Drug Discov. 2024. PMID: 38213150 Review.
-
Regulatory T Cells in Atherosclerosis: Is Adoptive Cell Therapy Possible?Life (Basel). 2023 Sep 18;13(9):1931. doi: 10.3390/life13091931. Life (Basel). 2023. PMID: 37763334 Free PMC article. Review.
-
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma.Vaccines (Basel). 2023 Aug 12;11(8):1357. doi: 10.3390/vaccines11081357. Vaccines (Basel). 2023. PMID: 37631925 Free PMC article. Review.
-
Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives.Life (Basel). 2023 Aug 1;13(8):1674. doi: 10.3390/life13081674. Life (Basel). 2023. PMID: 37629531 Free PMC article. Review.
-
Angiogenesis and Lymphangiogenesis in Medulloblastoma Development.Biology (Basel). 2023 Jul 21;12(7):1028. doi: 10.3390/biology12071028. Biology (Basel). 2023. PMID: 37508458 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials